Equities

Scholar Rock Holding Corp

Scholar Rock Holding Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)15.45
  • Today's Change0.45 / 3.00%
  • Shares traded829.00
  • 1 Year change+92.88%
  • Beta0.8868
Data delayed at least 15 minutes, as of Mar 27 2024 20:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Scholar Rock Holding Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of medicines for the treatment of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. The Company’s product candidate includes apitegromab, an inhibitor of the activation of latent myostatin for the treatment of spinal muscular atrophy (SMA) and is in the treatment of other myostatin-related disorders. Its product candidate also includes SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 (TGFb1) for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies. The Company is advancing multiple antibody profiles toward product candidate selection, including antibodies that selectively inhibit the activation of latent TGFb1 in the context of fibrotic extracellular matrix and that avoid perturbing TGFb1 presented by cells of the immune system.

  • Revenue in USD (TTM)0.00
  • Net income in USD-165.79m
  • Incorporated2017
  • Employees150.00
  • Location
    Scholar Rock Holding Corp301 BINNEY STREET, 3RD FLOORCAMBRIDGE 02142United StatesUSA
  • Phone+1 (857) 259-3860
  • Fax+1 (302) 655-5049
  • Websitehttps://scholarrock.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Viridian Therapeutics Inc314.00k-237.73m1.10bn96.00--4.01--3,500.19-5.32-5.320.0078.190.0007--3.083,340.43-51.37-55.59-54.93-60.32-----75,711.47-5,678.12----0.0437---82.28-48.16-83.05--15.08--
Arcutis Biotherapeutics Inc59.61m-262.14m1.10bn296.00--10.47--18.49-3.90-3.900.86020.91610.15080.4833.48201,371.60-66.31-65.64-74.24-71.7291.63---439.79-1,513.036.80-8.110.6947--1,517.09--15.83------
Verve Therapeutics Inc11.76m-200.07m1.10bn255.00--1.80--93.80-3.13-3.130.18327.310.0164--3.4046,109.80-27.94---29.43-------1,701.55------0.00--505.77---27.12------
SAGE Therapeutics Inc86.46m-541.49m1.14bn487.00--1.43--13.24-9.05-9.051.4413.320.0772--1.79177,527.70-48.37-21.88-52.66-23.3097.5099.63-626.32-131.50----0.00--1,024.84-0.8606-1.63---28.01--
Liquidia Corp17.49m-78.50m1.15bn136.00--21.87--65.52-1.21-1.210.26910.68910.1413--3.85128,588.20-63.43-55.02-71.31-62.6983.4982.18-448.89-474.59---26.140.4942--9.7545.23-91.40--66.93--
Mirum Pharmaceuticals Inc186.37m-163.42m1.18bn264.00--4.72--6.34-4.08-4.084.565.320.37293.374.05705,962.10-32.70-38.93-38.55-44.8874.76---87.68-190.714.19-79.670.552--141.85---20.45--21.81--
Belite Bio Inc (ADR)0.00-31.63m1.19bn20.00--12.87-----1.24-1.240.003.100.00----0.00-45.54---47.50--------------0.00-------150.09------
Scholar Rock Holding Corp0.00-165.79m1.20bn150.00--5.21-----1.99-1.990.002.960.00----0.00-49.55-38.14-55.26-44.31-------647.95----0.1817---100.00---23.26---45.61--
Pharvaris NV0.00-116.19m1.22bn65.00--5.81-----3.18-3.180.004.040.00----0.00-57.65---63.41-------------6.960.0019-------78.64------
Deciphera Pharmaceuticals Inc163.36m-194.94m1.23bn355.00--3.48--7.51-2.29-2.291.924.360.35220.17876.01460,157.80-42.03-44.54-52.63-52.2497.72---119.34-245.883.59--0.00--21.87---8.95---7.11--
MannKind Corp198.96m-11.94m1.25bn414.00------6.29-0.0464-0.04640.7087-0.91160.51652.5012.55480,584.50-3.10-26.07-3.99-37.8068.4559.68-6.00-57.613.310.50231.90--99.4248.1786.34--160.47--
Ligand Pharmaceuticals Inc131.31m53.82m1.26bn58.0024.521.7913.979.612.912.817.2639.920.16950.56424.152,264,035.006.9412.327.5012.9991.9981.6540.9880.3212.72--0.00001---33.09-12.181,131.21-17.8642.63--
Tarsus Pharmaceuticals Inc17.45m-135.89m1.30bn244.00--6.00--74.29-4.58-4.580.59395.760.0707--1.6471,504.10-55.09-31.56-61.63-33.8290.87---778.89-242.596.85--0.1315---32.42---118.86--279.39--
Collegium Pharmaceutical Inc566.77m48.16m1.31bn197.0046.376.676.622.310.88230.882312.536.130.48916.103.132,876,990.004.162.796.754.8057.5550.888.505.161.102.590.77340.0022.1715.11292.60---54.77--
AbCellera Biologics Inc38.03m-146.40m1.31bn586.00--1.13--34.57-0.5062-0.50620.13153.960.0251--1.1064,890.79-9.676.08-10.496.67-----384.9924.697.32--0.000.00-92.1733.91-192.35--70.96--
Data as of Mar 27 2024. Currency figures normalised to Scholar Rock Holding Corp's reporting currency: US Dollar USD

Institutional shareholders

71.81%Per cent of shares held by top holders
HolderShares% Held
Invus Public Equities Advisors LLCas of 31 Dec 202311.26m15.61%
Fidelity Management & Research Co. LLCas of 31 Dec 202310.41m14.44%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 20238.09m11.22%
Redmile Group LLCas of 31 Dec 20236.40m8.88%
BlackRock Fund Advisorsas of 31 Dec 20234.25m5.90%
Polar Capital LLPas of 31 Dec 20232.94m4.08%
The Vanguard Group, Inc.as of 31 Dec 20232.77m3.84%
Bellevue Asset Management AGas of 31 Dec 20232.17m3.01%
SSgA Funds Management, Inc.as of 31 Dec 20232.16m2.99%
Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 20231.34m1.86%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.